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META-ANALYSIS: RISK OF TICS WITH PSYCHOSTIMULANT USE IN RANDOMIZED,
PLACEBO-CONTROLLED TRIALS.
Stephanie C. Cohen, Jilian M. Mulqueen, Eduardo Ferracioli-Oda, Zachary D. Stuckelman, Catherine G.
Coughlin, James F. Leckman, and Michael H. Bloch. Child Study Center, Yale University School of
Medicine, New Haven, CT.

Clinical practice currently restricts the use of psychostimulant medications in children with
tics or a family history of tics for fear that tics will develop or worsen as a side effect of treatment.
Our goal was to conduct a meta-analysis to examine the risk of new onset or worsening of tics as an
adverse event of psychostimulants in randomized, placebo-controlled trials.
We conducted a PubMed search to identify all double-blind, randomized, placebo-controlled
trials examining the efficacy of psychostimulant medications in the treatment of children with
attention-deficit/hyperactivity disorder (ADHD). We used a fixed effects meta-analysis with risk ratio
of new onset or worsening tics in children treated with psychostimulants compared to placebo. We
used stratiﬁed subgroup analysis and meta-regression to examine the effects of stimulant type, dose,
duration of treatment, recorder of side effect data, trial design, and mean age of participants on the
measured risk of tics.
We identified 22 studies involving 2,385 children with ADHD for inclusion in our metaanalysis. New onset tics or worsening of tic symptoms were commonly reported in the
psychostimulant (event rate=5.7% (95% CI: 3.7% to 8.6%), I2 =72%, p<0.001) and placebo groups
(event rate=6.5% (95% CI: 4.4% to 9.5%), I2 =64%, p<0.001). The risk of new onset or worsening of
tics associated with psychostimulant treatment was similar to that observed with placebo (risk
ratio=0.99 (95% CI: 0.78 to 1.27), z=-0.05, p=0.96). Type of psychostimulant, dose, duration of
treatment, recorder of side effects, and participant age did not affect risk of new onset or worsening of
tics. Crossover studies were associated with a significantly greater measured risk of tics with
psychostimulant use compared to parallel group trials.
Meta-analysis of controlled trials does not support an association between new onset or
worsening of tics and psychostimulant use. Clinicians may want to consider re-challenging children
who report new onset or worsening of tics with psychostimulant use, as these symptoms are much
more likely to be coincidental rather than caused by psychostimulants.
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Of note, the following introduction is based on a review I wrote with my research
mentors of the clinical assessment of Tourette syndrome and tic disorders [1]. The
remainder of the thesis is also based on our published work [2]. Please see Appendix A
and Appendix B for a full copy of each article.

Introduction
Section 1. Background on Tics & Tourette Syndrome
Tourette syndrome (TS) was first described by the French neurologist, Gilles de la
Tourette, in 1885 as a “maladie des tics.” In his original case series describing the
syndrome that now bears his name, Gilles de la Tourette wrote about many of the
characteristics of the syndrome including: involuntary movements and sounds, markedly
enhanced startle reactions, a tendency to repeat both vocalizations (echolalia) and
movements (echopraxia), and uncontrollable verbal obscenities (coprolalia) [3]. Since
then, our knowledge of TS has progressed significantly, including advances in our
understanding of tics, their surrounding sensory phenomena, and the central role that
other co-occurring diseases, such as Attention Deficit Hyperactivity Disorder (ADHD)
and Obsessive-Compulsive Disorder (OCD), have on the overall clinical course of the
disorder. This introduction will focus on our current understanding of the diagnosis,
clinical characterization and assessment of tics as well as their clinical course. Because of
the large overlap between TS and ADHD, a background on use of psychostimulants and
tics will be provided as well.
Definition of tics:
Tics appear as sudden, rapid, purposeless motor movements or sounds that
involve discrete muscle groups. They are also stereotyped in that they will occur in a
similar manner each time they are performed. In comparison to some movement
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disorders or psychiatric conditions (e.g. Sterotypies, Chorea, or Dyskinesia), patients with
tics report the ability to suppress them, even if only for a short duration. However, they
report that suppression often causes discomfort. Almost any movement, sound, or
combination therein that the body can make can become a tic. Although some tics are
more mild (i.e. eye blinking), others can be more severe to the point of causing pain to
the patient (i.e. head or neck jerk). Apart from the physical consequences incurred by
them, tics and their associated neuropsychiatric symptoms can diminish patients' quality
of life, social and academic function, and lifetime achievements. They can also be very
troubling and disruptive to the patients' family, and many times the entire family needs
care and counseling [4]. Oftentimes, the tics themselves have less adverse effects than the
co-occurring disorders. For instance, a 2011 study measuring quality of life (QoL) in fifty
youth with TS found that symptoms of depression, OCD, and ADHD appeared to have a
widespread negative impact on QoL; however, increased tic severity and poor QoL were
not associated [5].
Tourette Syndrome and other tic disorders:
The prevalence of TS varies based on study design and location. An international
prevalence of 0.6% – 1% has been reported for mainstream schoolchildren, with the
disorder being 3–4 times more common in males than in females [6]. Data from the 2007
National Survey of Children's Health (NSCH) showed an estimated prevalence of 0.3%
among U.S. children aged 6–17 years [7]. This number may represent an underestimate
of TS prevalence since data were gathered from a parent- reported survey, and detection
might be imperfect for children with fluctuating levels of symptoms or limited access to
specialty health-care services [7]. Alternatively, TS prevalence may differ in prevalence
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worldwide due to either genetic or environmental differences. For example, TS has been
reported to be less common in African-American people and has been reported only very
rarely in sub-Saharan black African people [8]. Regardless, the phenomenology of TS is
similar in all cultures in which it has been reported [8].
TS is defined by the pediatric onset of both motor and vocal tics, lasting for at
least one year. Although TS is the most notorious cause of chronic tics, there are types of
tic disorders that are more common in children. Based on the Diagnostic and Statistical
Manual–5 (DSM-5) of the American Psychiatric Association, other tic disorders include:
Persistent (Chronic) Motor or Vocal Tic disorder (CMT), which is defined as
having motor or vocal tics (but not both) for more than one year; and Provisional Tic
Disorder, which is characterized by single or multiple motor and/or vocal tics for a
duration of less than one year [9]. Transient tics affect 15–25% of school-aged children
with the majority experiencing resolution of tics within several months [8, 10-12]. Other
Specified Tic Disorder or Other Unspecified Tic Disorder are the diagnostic terms used
for tic disorders that begin after age 18, are secondary to other factors such as substance
use (e.g. cocaine), toxins (e.g. carbon monoxide poisoning), or head trauma (e.g. physical
trauma, stroke, or encephalitis), or do not fit in the above-mentioned categories [9].
Table 1. Tic Disorders according to DSM-5
Diagnosis
Tourette's
Disorder

Type of Tics

Description of Tics

Multiple motor
and one or
more vocal tics

Tics may wax and wane in frequency but
have persisted for >1 year since first tic
onset

Persistent
(Chronic) Motor
or Vocal Tic
Disorder

Single or
multiple
motor or
vocal tics (but
not both)

Tics may wax and wane in frequency but
have persisted for >1 year since first tic
onset

Age of Onset
<18 years of age

<18 years of age
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Provisional Tic
Disorder

Other Specified
Tic Disorder

Unspecified Tic
Disorder

Single or
multiple
motor and/or
vocal tics
Motor or vocal

Tics have been present for <1 year since
first tic onset

<18 years of age

Tic disorder symptoms present, which
cause clinically significant distress or
impairment, but do not meet full criteria
for a tic disorder for a specific reason
(e.g., “with onset after age 18 years”)

Often used for
individuals that
have onset at >18
years of age

Motor or vocal

Tic disorder symptoms present, which
cause clinically significant distress or
impairment, but do not meet full criteria
for a tic disorder for a reason that is not
specified by the clinician, often because
there is insufficient information to do so

N/A

Tics also exhibit several characteristics that distinguish them from other common
childhood movement disorder such as stereotypies, choreas and dystonias. The
distinguishing characteristics of tics include (1) they wax-and-wane in severity, (2) the
character of the movements changes over time, (3) they are temporarily suppressible and
(4) they are typically associated with sensory phenomena. Table 2 contrasts TS with other
common movement and childhood psychiatric disorders confused with TS.
Table 2. Differential Diagnosis of Tic Disorders
Movement

Description


Tics








Stereotypies

Common Causes

Abrupt, stereotyped
coordinated movements or
vocalizations that often mimic
aspects of regular behavior
Wax and Wane
The character of the movements
changes over time
Temporarily suppressible
Premonitory urges are common
Exacerbated by stress and relieved by
distraction





Tourette’s Disorder
Persistent (Chronic) Motor or Vocal
Tic Disorder
Provisional Tic Disorder

Repetitive, purposeless, and
apparently voluntary movements






Autism
Pervasive Developmental Disorder
Mental Retardation
Stereotyped Movement Disorder
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Simple, random, irregular, and nonstereotyped movements
Has no premonitory component and
increases when the person is
distracted
Often flows from one body part to
another









Normal in children less than 8
months of age
Cerebral Palsy
Sydenham's Chorea
Hereditary choreas
Kernicteris
Lesch-Nyhan syndrome
hypoxia or stroke



Slow, protracted twisting movements
interspersed with prolonged states of
muscular tension








Drug-induced
Idiopathic torsion dystonia
Anoxia or stroke
Wilson's disease
Huntington's Disease
Parkinson's Disease



Slow, irregular, writhing movements.
Usually involving fingers and toes
but occasionally the neck
A “slow chorea”



See section on “chorea”

Brief, simple, shock-like muscle
contractions that may affect
individualized muscles or muscle
groups.



Physiologic: hiccups, anxiety, or
exercise- induced
Pathologic: Juvenile Myoclonic
Epilepsy, Metabolic
encephalopathies, Creutzfeldt-Jakob
Disease, Wilson's disease, and
hypoxia

Involuntary movement associated
with a specific voluntary act, i.e.
raising corner of mouth when closing
one's eyes




Chorea


Dyskinesia

Athetoid


Myoclonia


Synkinesis



Physiologic

Characterization of Tics:
Tics are characterized by their anatomical location, number, frequency, and
duration. They are also further described by their forcefulness or intensity and by their
complexity (ranging from simple to complex). The most widely-used rating scale of tic
severity is the Yale Global Tic Severity Scale (YGTSS), which includes separate scores
from 0–5 for number, frequency, intensity, complexity, and interference (the degree to
which planned actions or speech are interrupted by tics) of both motor and phonic tics
[13]. This tool has allowed for the standardization of tic severity across different studies
and research groups, aiding in the characterization and quantification of symptoms.
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Additionally, because the clinical characteristics of TS make it hard for clinicians
to diagnose and assess the severity of the condition, the Tourette Syndrome Diagnostic
Confidence Index (DCI) was created through a collaborative effort of an expert group of
clinicians. Based on the range and complexity of tics, their changeable nature, the
temporal features of tic expression, and associated subjective and cognitive experiences,
the DCI assigns a score from 0 to 100, which reflects the likelihood of having or ever
having had TS [14].
Other rating scales include the Shapiro Tourette Syndrome Severity Scale,
Tourette's Syndrome-Clinical Global Impression Scale, and the Hopkins Motor and
Vocal Tic Scale [15]. Standardized video recordings can also be used to count tics [16].
See Table 3 for a detailed comparison of various rating scales. For a detailed discussion
on these rating scales, please refer to a recently published review [17].
Table 3. Tic Rating Scales
Scale
Yale
Global
Tic
Severity
Scale
(YGTSS)

Citation
[13]

Informants Items
Clinician-rated;
Semistructured
interview
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Domains
Probed
Number,
frequency,
intensity,
complexity,
and
interference
from motor
and vocal
tics, and
overall
impairment

Strengths

Weaknesses

 Most widely
used
measure.
 Has tic
symptom
checklist
 Gives
separate
severity for
motor and
vocal tics
 Good interrater
reliability
 Sensitive
to change
with
treatment

 Insensitive to
change in
patients with
frequent and
severe tics.
 In individuals
with few phonic
tics small
changes in
symptomatology
can cause large
fluctuations in
ratings
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Tourette's
Syndrome
Severity
Scale
(TSSS)

[18]

Patients
and
collaterals
asked to
give
ratings

Tourette’s
Disorder
ScaleClinician
Rated
(TODSCR)

[19, 20]

Clinicianrated; semistructured
interview of
parent and
child
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How much tics
are noticed,
commented on,
seen as odd by
others and
degree of
impairment
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Motor and
Phonics Tics as
well as common
comorbid
conditions (such
as obsessions,
compulsions,
inattention,
hyperactivity,
aggression, and
emotional
disturbances)

Parent-rated;
self-report
regarding child

Tourette's
Disorder
ScalePatient
Rated
(TODS- PR)

N/A Measures
overall
severity of
each
individual tic
on a visual
scale

Hopkins
Motor and
Vocal Tic
Scale

[15, 21]

Separate
ratings by
family
member
and
observer

Tourette's

[22]

Self-report
35 Tic history,
involving parent pages prenatal and
and child
developmental
history and
family history.

[23]

Parent-rated,
self-report

Syndrome
Questionna
ire (TSQ)

Child
Tourette
Syndrome
Impairment
Scale

37

Overall
impairment
(and
impairment
from tics) in
school, home
and social
activities.

 Reliable
 Short
administration time

 Focuses
primarily on
social impact
from tics and not
on the severity of
tics themselves

 Provides
ratings of
common
comorbid
behavioral
symptoms.

 Severity ratings
include
symptoms
classified in
other DSM-5
disorders such as
ADHD, OCD,
MDD, anxiety
disorders, and
IED

 Can follow
separately
improvement in
specific
tics
 Easy to
administer

 Difficult to
aggregate data
across patients
 Does not have
separate
measures for
frequency,
intensity and
interference from
tics

 Provides
assessment
of many
potential
risk factors
for
Tourette
syndrome

 Time intensive
 Problems with
recall bias for
many parent
report items

 Provides
more
nuanced
with of
impairmen
t than
single-item
measures

 Most useful
when performed
in conjunction
with tic severity
measure
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Videotape
Ratings and
Tic Counts

[24, 25]

Videotape
subject for at
least 5
minutes.
Count motor
and vocal and
total tic
frequency.

N/A Tic frequency

 Objective
measure of
tic severity

 Labor-intensive
 Vulnerable to
sampling bias
because tics waxand-wane in
severity
 Requires
significant
amount of
equipment
 Does not
measure
impairment and
interference from
tics

Note: ADHD = Attention-Deficit Hyperactivity Disorder; OCD = Obsessive Compulsive
Disorder; MDD = Major Depressive Disorder; IED = Intermittent Explosive Disorder
Natural History of Tourette Syndrome:
The natural history of TS has been established based on clinical observations.
There is a clear progression of the disorder from the onset of symptoms to, in most cases,
full or partial regression of symptoms. Tics usually begin around 6–8 years of age, and
90–95% of TS cases have an onset of tics between the ages of 4–13 [26]. Simple motor
tics involving the eyes or face are usually the first to appear in a child with TS. They are
called simple because they involve a single contraction, such as a shoulder shrug or neck
stretch. Motor tics will typically progress in a rostral-caudal fashion and over time they
have a tendency to become more complex, involving contractions of groups of muscles in
a stereotyped, repetitive way [26]. As such, complex motor tics are often difficult to
distinguish from compulsive behaviors.
Phonic tics usually appear after the onset of motor tics and can also progress from
simple vocalizations to more complex ones. Although a distinction is made between
phonic and motor tics, it is a tenuous one as the sounds produced are a result of
contractions of laryngeal, respiratory, oral, or nasal musculature [27]. Simple phonic tics
are brief, meaningless vocalizations that often consist of a single sound, such as grunting,
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squeaking, or sniffing, while complex phonic tics can include uttering different words or
phrases. In the same category, echolalia (repeating the words or sounds of others),
palilalia (repeating oneself), and coprolalia (saying obscene words or phrases) are types
of complex phonic tics. Table 4 describes and gives examples of simple and complex
motor and phonic tics.
Table 4. Types of Tics
Motor
Simple Sudden, brief, short (usually <1 second), one group
of muscles (e.g. eye blinking, facial grimacing,
head jerk, shoulder shrug)
Complex Sudden, appear purposive, stereotyped, longer
duration, coordinated movements

Phonic
Fast, meaningless sounds/noises (e.g.
sniffing, throat clearing, grunting, or
high-pitched squeaks)
Syllables, words, or phrases; odd
patterns of speech with changes in
rate, volume, or rhythm

Echopraxia: copying gestures of others

Echolalia: repeating words or phrases
of others

Palipraxia: repeating one's own gestures

Palilalia: repeating one's own words or
phrases

Copropraxia: lewd and obscene gestures with hands
or tongue

Coprolalia: socially inappropriate
syllables, words, or phrases
expressed in a loud, explosive
manner

Dystonic: sustained, gyrating, bending, or twisting
movement or posture (e.g. blepharospasm,
oculogyric movements, mouth opening, shoulder
rotation)
Tonic: sustained, isometric contraction (e.g.
abdominal or limb tensing)
Self-injurious Behavior: tics that involve injuring
oneself (e.g. tongue or lip biting, or hitting one's
face)

Tics tend to wax and wane in severity and frequency. Both motor and phonic tics
arise in bouts over the course of the day, and they change in severity over weeks and
months. Thus, the amount and length of tic-free intervals throughout the day determines
to some extent the severity of the symptom. The tic itself can be more or less forceful,
which characterizes its intensity [28].
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By contrast, there are no factors known to affect the long-term course of tics.
However, the vast majority of children with tics improve. The severity of tics usually
peaks at about 10–12 years of age, and in one half to two thirds of cases, symptoms will
drastically reduce during adolescence [29] (Fig. 1). In the rare cases in which tic severity
persists into adulthood, tic symptoms are most severe, characterized by self-injurious
motor tics or coprolalic utterances [28].

Fig. 1. Average tic severity from age 2 to 18 years. Adapted with permission from [26].
In fact, in a recent study by Freeman et al., the overall prevalence of
coprophenomena was 19.3% in an international cross-sectional sample of 597 patients.
Only 15 of 220 individuals who had mildly-rated tics had coprolalia; whereas 42.6% of
the 108 patients with severe tics had coprolalia. The mean age of onset of coprolalia and
copropraxia was 5 years 4 months and 4 years 10 months, respectively, after the onset of
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tics. This delayed onset and greater percentage of coprolalia seen in patients with severe
tics is not surprising, as coprophenomena reflects more complex tics and comorbidity
patterns [30].
Other studies have also associated the presence of certain types of tics with
clinical course. A recent study by Martino et al. looked at the prevalence of eye tics in TS
patients. They found that of 212 patients, 201 or 94.8%, reported ever having eye tics in
their lifetime. They also discovered that overall tic severity positively correlated to
lifetime history of eye and/or eyelid/eyebrow movement tics. Furthermore, they found
that regardless of the type of tic at onset, patients with a lifetime history of eye movement
tics had an earlier onset of TS than those who had never had eye movement tics. These
findings suggest the possibility for a difference in the natural history of patients with and
without ocular tics [31].
Few studies have examined predictors of long-term outcome on
neuropsychological assessment and neuroimaging. One cohort that examined 43 children
with TS followed to young adulthood demonstrated that smaller childhood caudate
volume and poor Purdue Pegboard performance were associated with increased tic
severity in early adulthood [32, 33]. Purdue pegboard performance is a test of fine-motor
skill, and poor performance may be a sign of deficits in complex, visually guided or
coordinated movement that is likely mediated by circuits involving the basal ganglia.
Reduced caudate volume has been previously demonstrated to be a morphological trait of
TS on structural MRI [34, 35].
Sensory Phenomena surrounding tics:
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The outward manifestation of TS represents only a part of the symptomatology
experienced by most of our patients. In 1980, Joseph Bliss, articulately described his
careful observations from 35 years of self-study of the feelings and subjective events
surrounding his own tics. Much of what he described became the basis for future research
surrounding the sensory phenomena associated with tics. The term, “sensory
phenomena,” is now used as an all- encompassing term to describe such subjective
experiences as premonitory urges, “just- right” perceptions, or somatic hypersensitivity in
an effort to unify terminology across the literature [36].
Premonitory Urges:
Premonitory urges (PU) are uncomfortable sensory phenomena that typically
precede and are subjectively experienced as being the initiators of tics. Premonitory
urges, formerly deemed, “sensory tics,” can be experienced by individuals with tics and
are likened to the need to sneeze or itch or an inner feeling of restlessness, pressure or
mounting tension [37]. In a questionnaire administered to 135 patients with tic disorders,
it was shown that the anatomical regions with the greatest density of urges were the
palms, shoulders, midline abdomen, and throat [38]. Thus, premonitory urges are focal in
character and limited to specific anatomical locations. They can also vary in frequency,
intensity, and location. The performance of the tic itself is usually associated with a
momentary feeling of relief from this uncomfortable urge.
The premonitory urge has been studied in comparison with other normal
physiological urges, such as the urge to urinate, cough, blink or sleep. An urge is one
mode of processing internal or external sensory input into motor output. However, an
urge is not always perceived. Often the motor action can be triggered by sensory input
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alone outside of our awareness, and the action would thus be perceived as involuntary
[39].
Similarly, Bliss writes when describing the process of a tic that: “the inception
and emergence of a single action and its passage into the overt phase is so faint, subtle,
surreptitious, and lightening fast that rarely is it known to the subject that it exists at all”
[40].
If the action is delayed, an urge develops. This feeling of a need to act is different
from the sensation of the sensory input itself. Typically, the discomfort associated with
the premonitory urge builds up until the tic is performed. Some patients state that they
will voluntarily make tics in response to the urge in order to relieve themselves of the
mounting discomfort.
In 1994, Kane, then a graduate student with TS, wrote in reference to premonitory
urges, “these sensations are not mere precursors to tics; […] more than providing a signal
of imminence, the pre-tic sensation acts as the aversive stimulus toward which tics are
directed” [41].
Patients with TS have the ability to suppress tics temporarily but only at the
expense of mounting discomfort like suppressing a sneeze, itch, or the urge to urinate. In
fact, with prolonged suppression, the urge to tic can become so great that the action
occurs beyond the patients' control. In this way, tics have been called “un-voluntary,”
since they are neither voluntary nor involuntary. In contrast to normal urges, the urge to
tic is different in that the sensory input that generates the urge to tic is unknown, tics are
not key to survival – in fact, they are both nonessential and nonproductive –, and the
execution of a tic only temporarily reduces the intensity of the urge to tic [39]. Also,
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individuals with tics sometimes report the need to perform tics until they get the feeling
associated with it being “just right.”
It remains possible that abnormal perception or filtering of these sensory
phenomena may be central to the pathogenesis of TS (see “Sensorimotor gating” below).
Several individuals with tics have suggested that these premonitory urges may be as
characteristic of TS and as disruptive and distracting as the tics themselves. Some
individuals perceive premonitory urges and other sensory phenomena as being the “core”
of TS [42].
Furthermore, patients have reported an awareness of the premonitory urge helps
them suppress imminent tics because they are fore-warned of their arrival and can take
measures to suppress them. Along these lines, certain types of behavioral therapies have
been developed in order to take advantage of this awareness. Premonitory urges are
utilized in cognitive-behavioral interventions that include empirically supported
behavioral therapy [43] and exposure and response prevention [44].
Awareness of premonitory urges typically increases as children with TS become
older [45]. Individuals with TS have reported that they first became aware of their
premonitory urges on average 3.1 years after the onset of tic symptoms [38]. The delayed
onset of awareness of urges most likely represents the normal development selfawareness and the fact that younger children are less able to recognize and describe
bodily urges. Premonitory urges are experienced by most adolescents and adults with TS.
Eighty-two to ninety-two percent of patients will report experiencing premonitory urges
prior to motor and vocal tics [46, 47].
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Whether a tic is voluntary or involuntary has been the topic of much study. Some
have said, the tic is a voluntary action performed in an attempt to relieve an involuntary
urge [40]. Furthermore, in a 2003 study, 68% of 50 TS subjects described a motor tic as a
voluntary motor response to an involuntary sensation, as opposed to a completely
involuntary movement [47]. Also, in a study involving 135 individuals with TS, 92% of
individuals indicated that their tics were either fully or partially a voluntary response to
their premonitory urges. Also, in the same study, 84% of these subjects reported that their
tics were associated with a momentary feeling of relief [38].
The Premonitory Urge for Tics Scale (PUTS) is a rating scale designed to
measure the strength of these premonitory urges in tic disorders. Although premonitory
urges have been difficult to recognize and consistently report for youth under the age of
10, the scale was found to have excellent psychometric properties for children above the
age of 10 years, with PUTS scores correlating with tic severity as measured by the
YGTSS [48].
Table 5. Sensory Phenomena Rating Scales
Measure
Premonitory
Urge for
Tics Scale
(PUTS)

Citation(s)
[48]

# Items Domains Probed
Strengths

Easy
to
9 items
Frequency of
administer and
specific pre-tic
complete
related sensory
symptoms along
with relief after
tic completion

Limitations
 Difficult to
administer
with younger
children who
may not
recognize or
understand
urges
 Does not
capture other
common
sensory
phenomenon
in TS besides
premonitory
urges
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University
of Sao
Paulo
Sensory
Phenomena
Scale (USPSPS)

[49]

2 parts:
checklist
and
severity
scale

Frequency,
interference and
distress of
sensory
phenomena that
precede,
accompany, or
follow tics and
other obsessivecompulsive
spectrum
behaviors

Sensory
Gating
Inventory
(SGI)

[50]

124 items 6-point Likert
ratings
assessing 4
factors:
perceptual
modulation,
distractibility,
over- inclusion
or hyperattention, and
fatigue and
stress
vulnerability

Structured
Interview
for
Assessing
Perceptual
Anomalies
(SIAPA)

[51]

15 items

5-point Likert
ratings of:
hypersensitivity,
inundation and
flooding, and
selective
attention to
external sensory
stimuli for each
of the 5 sensory
modalities

 Probes other
sensory
phenomena
such as “just
right” feelings,
feelings of
incompleteness,
inner
restlessness.
 Has symptom
checklist to
identify
common
symptoms

 Does not have
separate
domains for
different types
of sensory
phenomena

 Has 4 subscales
related to
different types
of sensorimotor
gating deficits

 Not designed
specifically to
detect sensory
phenomena
associated
with tics

 Easier to
complete than
SGI

 Not designed
specifically to
detect sensory
phenomena
associated
with tics
 Has not been
demonstrate d
to be elevated
in tic disorder
patients

Somatic Hypersensitivity:
Sensorimotor gating describes the neurological processes of filtering out
redundant or unnecessary sensory stimuli from all possible environmental stimuli.
Individuals with TS (and schizophrenia) have consistently demonstrated deficits in
sensorimotor gating as compared to healthy controls. Prepulse inhibition (PPI) of startle
to a high-intensity stimulus is an experimentally measurable indication of sensorimotor
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gating. Prepulse inhibition of startle is defined as the inhibitory effect of a low-intensity
stimulus or “prepulse,” on the startle response to the subsequent same, but high-intensity
stimulus [52]. The prepulse is believed to activate brain mechanisms which suppress or
“gate” the processing of that stimulus for a brief window of time. Impaired PPI has been
shown in patients with TS, and recently lesions in the dorsomedial striatum have been
implicated in their diminished capacity for PPI [52]. Swerdlow has demonstrated PPI is
regulated by both norepinephrine and dopamine substrates, and clonidine can repair PPI
disrupted by cirazoline [53].
As hypothesized by these sensorimotor gating deficits observed in patients with
TS, many individuals describe hypersensitivity as being an important phenomenon
intertwined with other aspects of the disorder. A salient example of this phenomenon is
the extreme sensitivity to tags in new clothing experienced by some children with TS.
These experiences are described well in the following quotes:
“Because of the state of sensitization (combined with memory recall and attention
targeting), this site is the most difficult to extinguish. Paradoxically, for the same
reasons it is the one most likely to be extinguished first in any period of
remission” [40].
“All these sensory actions can dart from one to another with great speed and
varying intensities, at times escalating to a fever pitch of intensity and at other
times fading quickly away, to recur some other time. Often the effort to control
these wild sensations seems to be more than the human spirit can bear; there are
really only two choices: let it all hang out or keep fighting. However great the
confusion and diversity of sensory-related actions and sensations, only one of
these is active at any given moment. All others, residual and secondary, stand in
the wings, with their entrances and exits following so quickly on after the other
that it is very hard at times to be aware of their single movements” [40].
“Perhaps the best description for the sensory state of TS is a somatic hyperattention: It is not as itch-like as it is an enduring somatosensory bombardment. I
experience the TS state as one of keen bodily awareness, or a continual
consciousness of muscle, joint, and skin sensations. For example, when sitting in
a chair, I do not lose awareness of the tactile sensation of the seat against my
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body, nor can I ignore the deeper somatic sensations of what my back and legs
feel like” [41].
“How does a new tic get started? The activation of TS sites is dependent on a
combination of (1) attention direction and (2) various precipitants such as stress,
tactile and kinesthetic perceptions, previous sensitization of a site, inadvertent
pressure points anywhere on the body, memory recall of the earlier sites, and
phantom fixations. […] The subject's attention, for any of a multitude of chance
reasons, can fall on any potential site. Over seconds, minutes, or hours, the
attention shifts to numberless places via sounds, sights, touch, pressure,
discomfort, pain, temperature, or thoughts. In the normal person, these attentionexciting events can go relatively unnoticed. In the person with TS, anyone can set
off a TS action even though that person may be completely unaware of the
stimulating factor” [40].
In 2011, Belluscio et al. studied in detail the experience of sensitivity to external
stimuli in a case-control study of 19 TS patients and 19 age-matched healthy volunteers.
An in-depth interview and questionnaire revealed that 80% of TS patients reported
heightened sensitivity to external stimuli, with examples among all sensory modalities,
but with statistically significant heightened sensitivity to 4 of 5 sensory modalities
(sound, light, smell, and touch) as compared to the healthy volunteers [54]. They found
bothersome stimuli were characterized as “faint, repetitive or constant, and nonsalient,
whereas intense stimuli were well tolerated” [54]. Examples of such bothersome stimuli
include: rough fabrics, the constant pressure exerted by a shirt collar or a waistband, the
pressure of a chair or another person's arm. Patients also described a preference for strong
tactile stimuli such as having their skin scratched or receiving a massage. Furthermore,
these investigators did not observe in TS patients any greater ability to detect different
intensities of olfactory and tactile stimuli as compared to healthy volunteers. This led
them to suggest that the perceived sensitivities were the result of altered or impaired
central processing [54].
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Several rating scales have been designed to measure this hypersensitivity
experienced by those with TS. The University of Sao Paulo Sensory Phenomena Scale
(USP-SPS) was designed in 2005 in order to assess the severity and frequency of sensory
phenomena that precede, accompany, or follow tics and other repetitive behaviors, such
as compulsions or rituals [55]. Furthermore, in 2009 it was validated against other
established scales, such as the Yale-Brown Obsessive-Compulsive Scale, Dimensional
Yale-Brown Obsessive-Compulsive Scale, Yale Global Tic Severity Scale, Beck Anxiety
Inventory, and Beck Depression Inventory, as a reliable instrument for measuring the
presence and severity of sensory phenomena in individuals with OCD [49].
In addition to PPI as an experimental measure of sensorimotor gating, the
Structured Interview for Assessing Perceptual Anomalies (SIAPA) and the Sensory
Gating Inventory (SGI) are rating scales that were developed in order to quantify
sensorimotor gating impairment seen in TS and schizophrenic patients. SIAPA was
developed in 1999 as a way to measure perceptual anomalies, such as flooding or
inundation of sensory stimuli in individuals with schizophrenia. The interview employs
Likert ratings of perceived hypersensitivity, inundation, and selective attention to external
sensory stimuli [51].
Furthermore, Hetrick et al. created the self-report rating scale, Sensory Gating
Inventory (SGI) in an effort to expand upon the SIAPA scale by employing an empirical,
factor analytic procedure to assess and systematically identify the phenomenology and
major dimensions of sensory gating. The self-report rating scale also employs Likert
ratings of subjective experiences, such as: perceptions of heightened stimulus sensitivity,
sensory inundation, disturbances in the processes of focal and radial attention, and
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exacerbation of sensory gating-like anomalies by fatigue and stress. The SGI scale
demonstrated strong reliability and validity [50].
Exacerbating/Alleviating Factors:
Tic symptoms vary in frequency and intensity, and in addition to potential
neurological variation, it has been shown that certain environmental or contextual factors
will either exacerbate or alleviate tic symptoms in individuals with TS.
The results of 6 different descriptive studies looking at the effects of different
antecedent variables on tic severity show stress and anxiety appear to be the most
common factors associated with an increase in TS symptoms, while fatigue and boredom
also rank high on the list [56]. On the other hand, relaxation, concentration, and physical
exercise were antecedent factors shown to contribute to tic attenuation [56]. These studies
are limited by the fact that they describe aggregate data, thus removing individual
experiences from the descriptions, and they are subject to bias because data were
collected by self report and parental observation.
Experimental designs studying the impact of various antecedent factors on tic
expression show tic expression occurs more frequently in cases of direct, overt
observation, during easy reading assignments, and when the tics themselves are spoken
about. For instance, more tics were observed when children were overtly, as opposed to
covertly, observed by a video camera; and the presence of another person in the room did
not affect overall tic counts [57]. Also, direct observation revealed tics are aggravated by
easy reading assignments, reading in a quiet classroom, and by the period between
assignments [58]. Conversely, it has been shown that periods of focused attention to tasks
and reduced peripheral sympathetic tone inhibit tic expression [59]. Another study
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revealed tic-related conversations increase the frequency of phonic tics (not motor tics) as
compared to conversations that do not have to do with tics [60]. Additionally, instructions
to suppress tics have been shown to modestly reduce tic frequency, at least for 30
minutes, with adults demonstrating suppression more frequently. In this same study of 7
adults and children, tic suppression did not lead to the rebound effect of increased tic
frequency after the period of suppression, but the impact of suppression instructions on
strength of premonitory urges ratings remains unclear [61].
Furthermore, taken together, multiple studies have suggested stress, anxiety,
frustration, and tension are emotional variables often associated with an increase in tics
[56]. However, it remains unclear as to why certain emotions exacerbate tics and what
their effect is on premonitory urges. With regard to consequent factors that affect tic
expression, it has been shown reinforcing tic-free periods acts to reduce tic frequency,
while paying attention to the tics themselves or publicly commenting on tics increases
these symptoms [56].
Table 6. Exacerbating and Alleviating Factors
Tic Attenuation
Relaxation

Tic Exacerbation
Stress, anxiety, worry, frustration

Physical exercise, sports

Fatigue, tiredness

Concentration, study activity

Returning to school

Habitual, automatic actions

Boredom, waiting

Reading for pleasure

Emotional trauma

Leisure activity

Holidays, birthdays

Talking to friends

Working under pressure

Doctor visits

Overstimulation, multitasking

Verbal instructions to suppress tics and
rewarding/reinforcing tic-free periods

Tic-related conversation

Interaction with familiar people

Being alone

Socialization (30%), social gatherings (25%)

Social gatherings (42%), socialization (50%)
(presence of others/overt observation)
Transportation

Adapted from data in (Conelea and Woods, 2008) [56].
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Suppressing Tics:
One of the characteristics of tic symptoms is that they are suppressible, even if
only for a short while. However, as stated earlier, the act of suppression can lead to the
build-up of uncomfortable premonitory urges. In one study, 3 of 4 children who
demonstrated reliable suppression showed a pattern of higher subjective urge ratings
during suppression as compared to baseline [62].
Although tics can be suppressed, to do so requires more attention and energy from
the individual. For instance, in a study involving 9 children with TS, ages 9–15, accuracy
and performance on a distraction task was reduced while children were simultaneously
told to suppress tics as compared to free-to-tic conditions [63]. However, no significant
difference was demonstrated between tic frequencies during periods of reinforced
suppression and reinforced suppression plus a distraction task. This study demonstrates
accuracy on an attention-demanding task may be impacted if a child is simultaneously
trying to suppress their tics: a finding that has strong implications on school performance
for children with TS. This finding suggests school performance of children with TS may
be impacted not only by tics but by the attention devoted to suppressing tics and
highlights the importance of a supportive environment where negative feedback from
their peers and teachers in response to tics is minimized.
Stress has been shown to be one of the major factors associated with tic
exacerbation. In a study involving 10 youth with TS, ages 9–17, it was demonstrated that
stress impacts children's ability to suppress tics but not necessarily their baseline tic
frequency. Tic frequency was greater during periods of reinforced suppression plus a
stressor as compared to just reinforced suppression [64]. However, tic frequency was not
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different between free-to-tic baseline levels and periods when applied stress was added to
this condition [64].
Additionally, it has been shown that tic suppression rewarded for tic-free intervals
is more successful at reducing tic frequency than is just being told to suppress tics. For
instance, in a study design in which tokens were delivered both contingently on the
absence of tics and non-contingently, tic frequency was lower in 3 of 4 children during
the former condition. The success of reinforced tic suppression could be one of the
reasons children are seen to tic more at home than in the classroom because tic absence is
reinforced in the classroom by the avoidance of teasing from peers [65]. Alternatively, it
is possible tic frequency is greater at home than in the classroom because children
become more tired by the end of the day when they return home from school.
Finally, one concern with the use of reinforced tic suppression as a model for
therapy is the potential for a tic rebound effect, which describes an increase in frequency
of tics after suppression. However, studies have not supported such concerns. Although
tic frequencies have been shown to increase post-suppression as compared to during
suppression, they do not increase above pre-suppression levels [66]. Another study
demonstrated similar findings after repeated 2-hour sessions of Exposure and Response
Prevention (ER), a behavioral treatment program, consisting of habituation to
premonitory sensory experiences during prolonged tic suppression. The study
demonstrated successful ER as this treatment resulted in a reduction of tics by 91% as
compared to baseline. However, comparison of 15 minute pre- and post-suppression
measurements did not result in a significant increase in tic frequency [67]. Additionally,
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one study noted the absence of the rebound effect in the 5 minutes following reinforced
tic suppression during periods of up to 40 consecutive minutes [68].
Comorbidities:
The description of behavioral and emotional disturbances in patients with TS has
occurred since 1899, around the time the disorder was first described by Georges Gilles
de la Tourette himself [69]. In fact, comorbid neuropsychiatric disorders, the majority
being ADHD and OCD, have been shown to occur in up to 90% of TS patients in both
clinic and community settings [70]. Figure 2 depicts the time course of common
comorbidities in relation to tic symptoms, as experienced by patients with TS (Fig. 2).

Fig. 2. Clinical course of Tourette syndrome and associated conditions. Figure depicts
severity of premonitory urges, tics, or comorbid conditions symptoms associated with
Tourette syndrome. Width bars correspond to severity of symptoms of each condition
over time. Adapted with permission from [28].
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Obsessive-Compulsive Disorder:
Roughly one-third to one-half of individuals with TS experience recurrent
obsessive- compulsive (OC) symptoms [71-73]. Genetic, neurobiological, and treatment
response studies suggest there may be qualitative differences between tic-related forms of
OCD and cases of OCD not related to tics. Specifically, tic-related OCD has a male
preponderance, an earlier age of onset, a poorer level of response to standard antiobsessional medications, and a greater likelihood of first-degree family members with a
tic disorder [74]. Symptomatically the most common obsessive-compulsive symptoms
encountered in TS patients are obsessions concerning a need for symmetry or exactness,
repeating rituals, counting compulsions, and ordering/arranging compulsions [73]. Also,
obsessive-compulsive symptoms, when present, in children with TS, appear more likely
to persist into adulthood than the tics themselves [29]. OCD with comorbid tics is less
responsive to SSRI pharmacotherapy and more responsive to antipsychotic augmentation
than OCD in patients without tics [75, 76]. OCD patients with and without tic disorders
appear equally responsive to cognitive-behavioral therapy [76].
Baseline data from a study of 158 youth with a chronic tic disorder (TD) showed
children with comorbid OCD (53% of subjects) experienced more severe tics, increased
levels of depressive and anxious symptoms, heightened psychosocial stress and poorer
global functioning [77]. The authors concluded TD with OCD is a more severe subtype
of TD and describes children with more internalizing disorders than those without OCD
[77]. By contrast, another exploratory study involving 306 children with TD, OCD, or
TD + OCD, failed to show that those with TD + OCD exhibited increases in tic severity
as compared to those with TD alone [78].
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Attention-Deficit Hyperactivity Disorder:
Roughly 30–50% of children with TS are diagnosed with comorbid ADHD [72].
This rate of comorbid ADHD is higher in clinical samples. Although the etiological
relationship between TS and ADHD is unclear, it is clear individuals with both TS and
ADHD are at a much greater risk for a variety of poor outcomes including greater
academic and social impairment [79-83]. Children with TS are often regarded as more
aggressive, more withdrawn, and less popular than their classmates, and comorbidity with
ADHD is associated with these difficulties [84]. Surprisingly, levels of tic severity are
less predictive of peer acceptance than is the presence of ADHD [83]. Comorbid ADHD
symptoms in children with tics are responsive to similar pharmacological treatment as are
ADHD symptoms in children without tics [85]. Therefore, prompt screening of ADHD
symptoms in children with tic disorders is imperative. We suggest examination of recent
practice parameters for a thorough review of the diagnosis, assessment, and treatment of
ADHD [86, 87].
Impulse Control Disorders:
In addition to the high frequency of such comorbid conditions as ADHD and
OCD, many children with TS have been noted to exhibit rage attacks, self-injurious
behavior, inappropriate sexual activity, discipline problems, sleep disturbances, and other
forms of impulse control disorders. Disruptive, Impulse-Control, and Conduct Disorders
are currently listed as a category within the DSM-V [9]. “Impulsivity is defined as the
failure to resist an impulse, drive, or temptation that is potentially harmful to oneself or
others. It is evidenced behaviorally as carelessness; an underestimated sense of harm;
extroversion; impatience, including the inability to delay gratification; and a tendency
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toward risk-taking and pleasure- and sensation-seeking” [70]. Wright et al. review TS as
it relates to impulse-control disorders, specifically, intermittent explosive disorder (IED),
self-injurious behavior (SIB), and other forms of impulse-control disorder.
This type of disinhibited behavior is inextricably linked to tics. For instance, some
individuals will have the urge to make a loud vocal tic in a quiet library upon seeing the
sign, “Quiet Please.” Similarly, one can feel the need to jerk his shoulder after someone
lightly puts their hand on it. This type of behavior could represent the disrupted sensory
gating in that the light stimulus is bothersome and can create a site of unpleasant urge.
Furthermore, there is the example of a physicist during WWII, who had to relinquish his
job in a high energy physics laboratory because whenever he saw the sign, “Danger High
Voltage,” he had the strong urge to touch the apparatus. These types of tics are seen as
reflexive tics to specific sensory clues, but often appear as disinhibited or impulsive
behavior.
It is estimated between 23% and 40% of clinically-referred TS subjects report
distressing behavioral symptoms, such as sudden unpredictable anger, irritability, temper
outbursts, and aggression [70]. A part of intermittent explosive disorder, rage attacks
have been linked to TS since as early as 1998, when it was suggested individuals with TS
and another comorbid condition, such as ADHD or OCD, are more likely to also
experience rage attacks [88]. Since then, a study in 2008 showed that of 314 children in a
Danish cohort of TS patients, 109 experienced rage attacks. Interestingly, when
examining the presence of rage attacks within different subgroups, it was noted rage
attacks were present in the greatest percentage (70.6%) of children who have TS with
both ADHD and OCD. In those with TS and ADHD, 56.7% experienced rage, which is
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similar to the 50.9% of children with TS and OCD who experience rage. In those children
who have TS alone, 36.7% exhibited rage attacks [89]. These data could support the
suggestion that impulsivity and compulsivity are interlinked. Another hypothesis as to
why OCD is linked to rage attacks in TS patients is that the sudden, impulsive outbursts
of anger are a result of a disruption to routines that are linked to the compulsivity present
in these patients [70]. In 2003, a questionnaire was developed in order to screen TS
patients for episodic rage according to their symptoms. In this study, 48 children with TS,
ages 7–17, were screened to explore rage attack phenomenology, and the investigators
used a cluster analysis to identify four potential subgroups of TS with rage: specific urge
resolution, environmentally secure reactivity, nonspecific urge resolution, or labile nonresolving [90].
Furthermore, self-injurious behavior (SIB) has been consistently associated with a
subgroup of TS patients. Of the 9 patients described by Gilles de la Tourette in 1885, 2 of
them were described as exhibiting SIB. Self-injurious behavior has been reported in
anywhere between 14.8% and 29% of TS subjects [91, 92]. Additionally, the proportion
of SIB present in those with TS is higher in those with comorbid ADHD and who are
older in age. In those patients with ADHD and TS, age of onset of SIB was 7.4 years, as
compared to 10 years in those without ADHD [91]. Examples of types of SIB noted are
biting one's tongue or lip, head-banging, body punching/slapping, head or face
punching/slapping, body-to-hard-object banging, and poking sharp objects into one's
body [70].
The co-occurrence of impulse-control disorders and TS has further implications
on the cognitive aspects of these individuals. They can exhibit the inability to delay
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gratification, the tendency toward making decisions based on immediate reward, they are
distractible, and they are generally disinhibited, all of which can lead to behavior that
does not comply with cultural norms. If impulsivity and compulsivity are thought to be
opposite ends of a spectrum, TS would be considered a mixture of the two. While
compulsions are driven by an attempt to reduce anxiety, impulsions are driven by an
attempt to obtain arousal and gratification [70].
Concluding Thoughts:
Tourette syndrome is a neuropsychiatric disorder characterized by multiple motor
and vocal tics. In the majority of children with TS, tic symptoms diminish significantly
during adolescence. Most individuals with TS experience associated sensory phenomena
such as premonitory urges and somatic hypersensitivity that are often as distressing as the
tics themselves. On the other hand, for many individuals with TS, the tics are neither the
most prominent nor distressing part of the disorder. The majority of individuals with TS
reaching clinical attention have common comorbid conditions such as ADHD, OCD and
impulse control disorders. Proper diagnosis and treatment of TS involves appropriate
evaluation and recognition, not only of tics, but also of these associated conditions.
Section 2. Psychostimulants and tics:
Psychostimulants are recommended as the first line pharmacologic treatment for
children with ADHD [87]. Psychostimulants have demonstrated a larger effect size when
compared to placebo, as compared to alternative pharmacological treatments for ADHD
[85]. Randomized controlled trials have demonstrated that psychostimulants are more
effective than behavioral treatments for ADHD for at least 14 months after the start of
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treatment [93]. When ADHD is present in children with tics, the symptoms of ADHD
typically cause greater impairment in academic performance, social relationships, and
neuropsychological performance, especially executive functioning, than the tics
themselves [81-83, 94, 95]. Psychostimulants have been shown to be equally efficacious
in treating ADHD symptoms in children with ADHD and comorbid tics as in children
with ADHD alone [85].
Clinical practice currently restricts the use of psychostimulant medications in
children with ADHD and comorbid tics. The limited use of psychostimulants in patients
with ADHD and comorbid tic symptoms is likely partially attributable to warnings placed
on the medications by regulatory agencies. The Food and Drug Administration (FDA)
currently requires that psychostimulants list tics and/or a family history of a tic disorder
as a contraindication (methylphenidate) or significant adverse reaction (methylphenidate
and amphetamines) to their use [96, 97]. FDA labeling warns parents that
psychostimulants “should not be taken by their child” (methylphenidate) and/or “may not
be right for your child” (amphetamines) if they have tics [98, 99].
Amphetamine/Dextroamphetamine labeling also warns the public to “use with caution in
patients with Tourette’s syndrome; stimulants may unmask tics” [100]. The FDA
warnings resulted largely from a series of case reports and case series, which were
published in the 1970s and 1980s [101-111]. A particularly influential case series of 15
children who developed tics while on psychostimulants helped lead the FDA in 1983 to
require listing contraindications and significant adverse reactions to psychostimulant
medications [112].
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Since then, however, multiple randomized controlled trials (RCTs) have
demonstrated no effect of psychostimulants on tics [113-116]. In fact, an NIH- and
Tourette Syndrome Association-funded trial examining treatment of ADHD in children
with tics concluded “that prior concerns that MPH worsens tics and that the drug should
be avoided in patients with tics may be unwarranted” [113]. Recent meta-analyses
examining pharmacological treatment of children with tics and ADHD demonstrated that
methylphenidate did not significantly worsen tic symptoms and was beneficial in treating
ADHD symptoms in children with both conditions [85, 117].
There is, however, strong biological rationale to suggest that psychostimulants
might exacerbate tics. Methylphenidate and dextroamphetamine induce stereotypies in
rats in a dose-dependent manner [118-120]. Stimulant-induced stereotypies in rodents are
hypothesized to be an animal model for tic disorders [121]. Furthermore,
psychostimulants have been demonstrated to increase dopamine in the synaptic cleft
[122] whereas the most effective anti-tic medications available, antipsychotic
medications, act as dopamine antagonists [28, 123, 124].
On the other hand, the timing of onset of ADHD and Tourette syndrome
represents a possible confounder. Roughly 20% of children with ADHD go on to develop
a chronic tic disorder [125]. When ADHD and tics co-occur in an individual, the onset of
ADHD typically precedes that of tic symptoms by 2 to 3 years [28]. Therefore, it is
difficult to determine whether the tics are a result of a side-effect of psychostimulants or
if they were to occur anyway, as children with ADHD are at higher risk of developing
tics regardless of medication use. Also, tics in Tourette syndrome typically wax and
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wane in severity, so it is unclear whether a patient’s tics are going to naturally increase at
a given time or if the increase is a result of psychostimulant side-effects.
Clinicians are uncertain regarding use of psychostimulants in children with
existing tics or a family history of tics because of conflict between strong FDA labeling
contradicting psychostimulant use in this population and randomized, controlled trial and
meta-analysis data suggesting efficacy without any apparent risk in the same population.

Statement of Purpose and Hypothesis
The goal of this meta-analysis is to provide an evidence base for future guidelines,
warnings, and clinical decisions for the use of psychostimulants in children who develop
tics after psychostimulant use or are judged to be at increased risk of developing tics prior
to psychostimulant use. We will examine all available data on side-effects in previous
randomized, placebo-controlled trials of psychostimulants in childhood ADHD to
determine the risk of new-onset or worsening of tics associated with psychostimulants
compared to placebo. We will conduct secondary analyses to examine the effects of
psychostimulant type (methylphenidate vs. mixed amphetamine salt derivatives, long
versus short-acting formulations), dose, duration, recorder of side-effects, trial design,
and participant age on the risk of tics with psychostimulant treatment.

Methods
Search Strategy for Identification of Studies:
Two reviewers (JMM and EFO) searched the electronic database of PubMed on
August 18, 2013 for relevant studies using the search: (Attention deficit disorder with
hyperactivity OR ADHD OR ADDH OR hyperactiv* OR hyperkin* OR “attention
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deficit*” OR “brain dysfunction”) AND (methylphenidate OR Ritalin OR Metadate OR
Equasym OR Daytrana OR Concerta OR Dextroamphetamine OR amphetamine OR
Adderall OR Vyvanse OR Dexedrine OR Dextrostat). The search only utilized
randomized controlled trials. The references of appropriate papers on the safety and
efficacy of psychostimulant medications were also searched (by SCC) for citations of
further relevant published and unpublished research.
Selection of Studies:
The titles and abstracts of studies obtained by this search strategy were examined
by two reviewers (JMM and EFO) to determine inclusion in this meta-analysis. Any
discrepancies were resolved by a final reviewer (MHB). Authors (SCC, CGC, and JMM)
re-checked this work to make sure the database created was accurate. Eligibility for the
study was based upon analysis of the full articles for the following criteria (1) they are
randomized, double-blind, placebo-controlled clinical trials of psychostimulant
medications (methylphenidate or dextroamphetamine derivatives) compared with placebo
and (2) participants included are children and adolescents less than 18 years of age
diagnosed with ADHD or hyperkinetic disorder by explicit criteria i.e. DSM or ICD
criteria. Exclusion criteria for the studies included if (1) the study was not published in
English, (2) the study population included only patients with ADHD plus another primary
comorbidity i.e. mental retardation, pervasive developmental disorder, oppositional
defiant disorder, tics, or anxiety, (3) the medication of interest was given for less than 7
days in duration, (4) there were fewer than 10 subjects (crossover design) or fewer than
20 subjects (parallel design), and (5) the primary goal of the trial was not treatment for
ADHD (e.g. studies which were primarily concerned with neuroimaging or
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neuropsychological measures were excluded). We required medication/placebo each to
be given for at least 7 days in trial because the authors a priori decided that this was the
minimum required time needed in order to be confident regarding a change in tic
symptoms. A 7-day assessment period is similar to that utilized for common clinical
rating scales of tic symptoms such as the Yale Global Tic Severity Scale [13]. We
additionally restricted trials to treatment trials as studies utilizing non-treatment related
outcome measures such as MRI, EEG or neuropsychological testing were less likely to
systematically assess side-effects of medications.
Meta-Analytic Procedures:
Data was extracted by independent reviewers (SCC, JMM, CGC, and ZDS) on
specially designed Microsoft Excel spreadsheets. Our primary outcome measure was the
proportion of children reporting tics as a side-effect of medication. When possible,
clinician-rated side-effect measures were utilized as the main outcome measure. When
this information was unavailable, participant-rated, parent-rated, or teacher-rated sideeffect measures were used. Reviewers additionally gathered data on trial medication, trial
design, maximum daily medication dose, number of participants, mean age of
participants, duration of active treatment in trials, who recorded side-effect ratings, and
other relevant attributes and results of the studies. Any disagreement among reviewers
was mitigated through discussion and the procurement of more information from the
study investigators when possible. When agreement could not be attained between the
initial reviewers, the senior investigator (MHB) resolved all disputes. When information
about proportion of tics was not available in the original manuscripts, the corresponding
author was contacted (by SCC and CGC) for further information. If contacting the
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corresponding author was ineffective, pharmaceutical company databases were searched
(by CGC) for the data.
All statistical analyses were completed (by MHB) in Comprehensive MetaAnalysis Version 2. For our outcome measures of interest, proportion of subjects
experiencing tics was analyzed using pooled risk ratio (RR). Absolute risk difference
(ARD) and number needed to harm (NNH) were also reported for the primary outcome as
both the absolute and relative risks are clinically relevant when considering the use of
medications. For all outcome measures, 95% confidence intervals (CIs) were conveyed. A
fixed-effects model for meta-analysis was used, as well as a random-effects model in
sensitivity analysis. Publication bias was assessed by plotting the effect size against
standard error for each included trial (i.e., funnel plot). In addition, publication bias was
statistically tested by the Egger’s test and by determining the association between sample
size and effect size in meta-regression. We additionally reported the risk of new-onset or
worsening of tics in both the psychostimulant and placebo groups in order to assist
clinicians in decision-making. We report results of a random effects model for these data
as it is clear there was significant heterogeneity in how tics were assessed and the
frequency that tics were reported within the placebo and psychostimulant groups based on
trial methodology.
For secondary analyses several subgroup analyses and meta-regressions were
accomplished. Stratified subgroup analyses were conducted based on (1) type of
psychostimulant (methylphenidate vs. mixed-amphetamine derivatives), (2) duration of
action of medications (long-acting vs. short-acting psychostimulants), (3) recorder of
side-effect data, and (4) trial design (crossover vs. parallel group trials). We utilized the
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test for subgroup differences (between group heterogeneity chi-square) in the mixedeffects model of CMA to test for subgroup differences. Meta-regression analysis was
used to examine the effect of (1) maximum daily dose of psychostimulants utilized in
trials, (2) length of active psychostimulant treatment, and (3) age of participants on the
risk of developing new-onset or worsening of tics with psychostimulants compared to
placebo. All daily doses of psychostimulants were converted into methylphenidate
equivalents using previously described methodology [126]. Our threshold for statistical
significance was p<0.05 for the primary analysis, as well as for all stratified subgroup
analyses and meta-regression.

Results
Included Trials:
Fig. 3 depicts the selection of trials for this meta-analysis. A total of 815
references were identified in PubMED. A total of 92 trials were eligible for inclusion. Of
these 92 trials, 16 trials published data on tics as a side-effect of psychostimulant
medication. Authors of 6 additional trials responded to email requests with unpublished
data regarding the risks of tics in psychostimulant trials. Therefore, a total of 22 trials,
involving 2385 participants, were included in our meta-analysis [127-148]. The
characteristics of included trials are depicted in Table 7.
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Fig. 3. Selection of studies. Note: ADHD = attention-deficit/hyperactivity disorder
Table 7. Characteristics of Included Trials in the Meta-Analysis of the Risk of Tics with
Psychostimulants.
Authors

Year

Medication

Stimulant
Class

Duration
of Action

Maximum
Dose

Design

N

Crossover

Duration
of Active
Treatment
4 week

37

Mean
Age
(years)
8.9

Werry et
al. [127]
GittelmanKlein et al.
[128]
Werry et
al. [129]
Rapport et
al. [130]
Barkley et
al. [131]
Buitelaar et
al. [132]
Stein et al.
[133]
Gillberg et
al. [134]
Firestone
et al. [135]
Pliszka et
al. [136]

1974

MPH IR

MPH

Short

1976

MPH IR

MPH

Short

0.5 - 1
mg/kg/day
60 mg/day

Parallel

4 weeks

80

8.6

1980

MPH IR

MPH

Short

0.4
mg/kg/day
15 mg/day

Crossover

3-4 weeks

30

8.4

1985

MPH IR

MPH

Short

Crossover

1 week

12

6-10

1990

MPH IR

MPH

Short

Crossover

7-10 days

82

8.2

Parallel

4 weeks

21

9.2

Short

0.5 mg/kg
BID
10 mg
BID
20 mg TID

1996

MPH IR

MPH

Short

1996

MPH IR

MPH

Crossover

1 week

25

8.0

1997

MAS IR

AMP

Short

45 mg/day

Parallel

3 months

56

9

1998

MPH IR

MPH

Short

Crossover

7-10 days

32

4.8

MPH IR

MPH

Short

0.5 mg/kg
BID
50 mg/day

2000

Parallel

3 weeks

58

8.1

Pelham et
al. [137]

2001

MAS IR

AMP

Short

30 mg/day

OROS®
MPH
MPH IR

MPH

Long

54 mg/day

Crossover

1 week

68

9.1

MPH

Short

15 mg TID

38
Wolraich
et al. [138]

2001

OROS®
MPH
MPH IR

MPH

Long

54 mg/day

MPH

Short

15 mg TID

Parallel

4 weeks

282

9.0

Greenhill
et al. [139]
McCracken
et al. [140]

2002

MPH MR

MPH

Long

60 mg/day

Parallel

3 weeks

316

9

2003

MAS XR

AMP

Long

30 mg/day

Crossover

1 week

49

9.5

MAS IR

AMP

Short

10 mg/day

Stein et al.
[141]
Findling et
al. [142]

2003

OROS®
MPH
EqXL

MPH

Long

54 mg/day

Crossover

1 week

47

9

MPH

Long

60 mg/day

Parallel

3 weeks

318

9.5

MPH IR

MPH

Short

Gorman et
al. [143]

2006

MPH IR

MPH

Short

Crossover

3 weeks

41

9.1

Findling et
al. [144]

2008

MPH Patch

MPH

Short

Parallel

2 weeks

274

8.7

MPH

Long

Newcorn et
al. [145]
Silva et al.
[146]

2008

OROS®
MPH
OROS®
MPH
dMPH ER

30 mg
BID
1 mg/kg
divided
daily
30 mg
9hr/day
54 mg/day

MPH

Long

54 mg/day

Parallel

6 weeks

293

10.2

MPH

Long

30 mg/day

Crossover

1 week

82

9.4

MPH MR

MPH

Long

54 mg/day

Solanto et
al. [147]
Lee et al.
[148]

2009

MPH IR

MPH

Short

50 mg/day

Crossover

1 week

25

8.8

2011

MPH IR

MPH

Short

0.5
mg/kg/day

Crossover

1 week

157

9.0

2006

2008

Note: AMP = amphetamine; BID = twice daily; dMPH = dexmethylphenidate; EqXL =
Equasym XL; IR = immediate release; MAS = mixed amphetamine salts; MPH =
methylphenidate; MR = modified-release; MTS = methylphenidate transdermal system;
OROS = trademarked acronym denoting Osmotic Controlled-Release Oral Delivery
System; Ref = reference; TID = 3 times daily; XR/ER = extended-release.

Risk of new-onset or worsening of tics with psychostimulants:
Meta-analysis of 22 studies involving 2385 participants demonstrated no
significant increase in the risk of new-onset or worsening of tics when comparing
psychostimulant to placebo (Fig. 4), RR=0.99 (95% CI: 0.78 to 1.27), z=-0.05, p=0.96.
There was no significant heterogeneity between trials (I2 =12.7%, p=0.28) or evidence of
publication bias (Egger’s test: p=0.88). A random effects model produced similar
estimates of risk when examined in a sensitivity analysis (RR=0.97 (95%CI: 0.72 to
1.32), z=-0.18, p=0.86).
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Fig. 4. Relative risk of tics with psychostimulants compared to placebo. Note: Forest plot
comparing the relative risk of tics in participants treated with psychostimulants compared
to placebo in short-term, randomized-controlled trials. Meta-analysis demonstrated no
significant difference in the risk of tics with stimulants compared to placebo (risk ratio =
0.99, 95% confidence interval = 0.78 to 1.27, z = -0.05, p = 0.96).
There was also no evidence of increased risk of new-onset or worsening of tics
when examining absolute risk difference of tics with psychostimulants compared to
placebo (Fig. 5), ARD=0.001 (95% CI: -0.009 to 0.011), z=0.18, p=0.86). There was no
significant heterogeneity among trials (I2 = 9.6%, p=0.32) or evidence of publication bias
(egger’s test: p=0.88). A random effects model produced similar estimates of risk when
examined in a sensitivity analysis (ARD=0.001 (95% CI: -0.011 to 0.013), z=0.16,
p=0.88.
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Fig. 5. Absolute risk difference of tics between psychostimulants and placebo. Note:
Forest plot depicting the absolute risk difference of tics in participants treated with
psychostimulants compared to placebo in short-term, randomized-controlled trials.
Meta-analysis demonstrated no significant difference in the risk of tics with stimulants
compared to placebo (absolute risk difference = 0.001, 95% confidence interval = -0.009
to 0.011, z = 0.18, p = 0.86).
In random effects meta-analysis, 5.7% of children in the psychostimulant arms of
trials reported new onset or worsening of tics (event rate=5.7% (95% CI: 3.7% to 8.6%),
I2 = 72%, p<0.001). However, the event rate for new-onset or worsening of tics was
higher in the placebo arms of included trials (event rate=6.5% (95% CI: 4.4% to 9.5%),
I2 = 64%, p<0.001).
Methylphenidate vs. Amphetamine Derivatives:
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Stratified subgroup analysis demonstrated no significant difference in risk of newonset or worsening of tics (test for subgroup differences χ2=0.26, p=0.61) between
methylphenidate derivatives (RR=1.02 (95% CI: 0.78 to 1.33), k=20, z=0.14, p=0.89) and
amphetamine derivatives (RR=0.84 (95% CI: 0.42 to 1.68), k=4, z=-0.49, p=0.63).
Long- vs. Short-acting psychostimulants:
Stratified subgroup analysis demonstrated no significant difference in risk of newonset or worsening of tics (test for subgroup differences χ2=0.22, p=0.64) between shortacting (RR=1.04 (95% CI: 0.76 to 1.43), z=0.25, p=0.80) and long-acting
psychostimulants (RR=0.92 (95% CI: 0.62 to 1.38), z=-0.40, p=0.69).
Psychostimulant Dose:
Meta-regression demonstrated no significant association between dosage of
psychostimulants and the risk of new-onset or worsening of tics (β=-0.0023 (95% CI:
-0.0142 to 0.0097), z=-0.37, p=0.71). There was no significant association between
dosage of psychostimulants and risk of new-onset or worsening of tics when analysis was
restricted to methylphenidate (β=-0.0005 (95% CI: -0.0159 to 0.0150), z=-0.06, p=0.95)
or amphetamine derivatives (β=-0.0028 (95% CI: -0.0280 to 0.0224), z=-0.22, p=0.83).
Duration of Active Treatment:
Meta-regression demonstrated no significant association between duration of
active treatment and the risk of new-onset or worsening of tics associated with
psychostimulant medication (β=-0.010 (95% CI: -0.022 to 0.002), z=-1.69, p=0.09).
Recorder of Side-effect Data:
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Stratified subgroup analysis demonstrated no significant difference in risk of newonset or worsening of tics based on whether clinicians or non-clinical informants (parents
and/or teachers) were rating tic outcomes (test for subgroup differences χ2=1.49, p=0.22).
The relative risk of tics was non-significantly lower when utilizing clinician recorders of
tics (RR=0.72 (95% CI: 0.41 to 1.29), z=-1.10, p=0.28) rather than non-clinical report
(RR=1.08 (95% CI: 0.82 to 1.42), z=0.53, p=0.59).
Trial Design:
Crossover studies reported a significantly greater association of new-onset or
worsening of tics with psychostimulants compared to parallel-group studies (test for
subgroup differences χ2=5.3, p=0.02). However, neither crossover trials (RR=1.23 (95%
CI: 0.90 to 1.68), z=1.3, p=0.19) nor parallel-group studies (RR=0.67 (95% CI: 0.44 to
1.02), z=-1.88, p=0.06) reported a significant association of tics with psychostimulant
use.
Age of Participants:
Meta-regression demonstrated no significant association between participants’ age
and measured risk of new-onset or worsening of tics with psychostimulant medications
(β=-0.39 (95% CI: -0.83 to 0.05), z=-1.75, p=0.08).

Discussion
Meta-analysis demonstrated no statistically significant relationship between
psychostimulant use and new-onset or worsening of tics in children with ADHD.
Specifically, the relative risk of new-onset or worsening of tics was 0.99 (95% CI: 0.78 to
1.27) indicating no evidence of an association between psychostimulants and tics.
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Furthermore, we found no association between risk of new-onset or worsening of tics and
dosage, type or duration of use, psychostimulant agent, or recorder of side-effect data.
Taken together, data from this meta-analysis is most consistent with an absence of a risk
of new-onset or worsening of tics with psychostimulant medications. However, the
power of this meta-analysis is not sufficient to rule out the possibility of a small increased
risk of tics with psychostimulant use. However, based on the available data, it remains
equally likely that psychostimulants reduce the risk of tics as they do raise the risk of tics.
Current evidence from this meta-analysis and previous work examining the effects
of psychostimulants in children with tics and ADHD does not support the clinical practice
of restricting the use of psychostimulants in children with tics or at high risk of
developing tics [98, 99]. Previous meta-analysis examining the effects of
methylphenidate in children with ADHD and comorbid tics demonstrated that
psychostimulants appear to have a similar effect size in reducing ADHD symptoms in
children with comorbid tics as in children without comorbid tic disorders [85].
Furthermore, there was no evidence that psychostimulants worsened tic symptoms in
children with both ADHD and tics [85]. Randomized controlled trials in children with
ADHD and tics have further demonstrated that combination treatment with
methylphenidate and clonidine is more effective than either medication alone [113]. Our
meta-analysis extends upon these previous results by demonstrating that there is no
increased risk of new-onset or worsening tics with psychostimulant use compared to
placebo in meta-analysis of randomized, placebo-controlled trials in children with ADHD
alone.
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The results of this meta-analysis also provide strong support for re-challenging
children (or even continuing children on psychostimulants) who develop tics that are
temporally related to the initiation of psychostimulants. Assuming the absolute risk
difference of 0.001 observed in the meta-analysis, the number needed to harm for newonset or worsening tics with psychostimulants is 1000 (95% CI: 77 to ∞). If additionally
assuming the baseline risk of experiencing new-onset tics over short-term trials of
medications is equivalent to the 6.5% observed in the placebo arms of randomized,
controlled trials of psychostimulants then in a child who develops tics shortly after
initiating psychostimulants, the tics are 65-fold more likely to be the result of coincidence
than caused by the medication. Even assuming the highest risk of tics ( 0.011 -- at the
upper bound of the 95% confidence interval of absolute risk difference), when new-onset
or worsening of tics appear after the initiation of psychostimulants, the tics are 6-fold
more likely to be a result of coincidence than be caused by the medications. Given the
absence of data suggesting psychostimulants make existing tics worse [85, 113], rechallenging appears reasonable, whether or not the tics persist after discontinuation of the
psychostimulant. Re-challenging appears particularly advisable in children whose ADHD
does not respond sufficiently to other medications such as alpha-2 agonists and
atomoxetine, which are used to help ADHD and may additionally help improve tics
symptoms [124, 149, 150].
There are several limitations to this meta-analysis that may have affected its
findings. Foremost among these limitations is the fact that a limited number of
randomized, placebo-controlled trials of psychostimulants for children with ADHD
actually reported on the frequency of tics as side-effects. The selective reporting of tics in
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side-effect data, if it existed, could lead to publication bias that would likely exaggerate
the association between tics and psychostimulants. Many trials only report side-effects
that were above a certain percent threshold in the active treatment group or were
statistically different between groups. This practice would also lead to an inflated
estimate of the association between psychostimulants and tics, as trials with increased
associations would be selectively published and included in our meta-analysis. In order
to minimize this potential bias, we emailed authors of potentially eligible trials that did
not include data on tics in order to obtain additional data to include in the meta-analysis.
However, many authors were unresponsive or did not have available data from the trial,
so this potential bias should not be discounted. Another potential limitation is the
inclusion of crossover trials in addition to parallel group trials in this meta-analysis. We
made the decision to include crossover trials to maximize power in our meta-analysis.
Crossover trials of psychostimulants were designed using washout periods of sufficient
time to eliminate any beneficial effects of psychostimulants before the start of the next
phase of the trial. It remains quite possible that if tics occurred as an adverse event in
crossover trials, they might still carryover to the next trial phase and thus dampen our
ability to detect tics as an adverse effect of treatment. However, stratified analysis
demonstrated an increased measured risk of tics with psychostimulants in crossover
studies compared to parallel-group studies, arguing against this phenomenon occurring.
An additional potential limitation is the heterogeneity in how tics were assessed as a sideeffect between trials – some trials relied on parent-report, whereas others included direct
observation of subjects. We conducted stratified subgroup analysis based on whether or
not a clinician was rating side-effects. We did not observe any significant effect based on
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who was rating side-effect symptoms. Additionally, some trials require significant
impairment for side-effects to be reported while others do not. Because of the manner in
which tics are reported as a side-effect in trials, we are unable to determine whether
individual reported adverse events in trials were due to (1) a new-onset of tics or (2)
worsening of pre-existing tics. We therefore are only able to comment on the aggregate
risk of either of these two events occurring but not of each event individually. It should
also be emphasized that our data only applies to use of psychostimulants within the
recommended therapeutic dose range. Both data in animal models and children with tics
has suggested that supratherapeutic doses of psychostimulant medications may worsen
tics [114, 118-120]. Another limitation to this meta-analysis is the fact that the studies
included in our meta-analysis do not have available data on whether tics resolve or persist
after medication or placebo discontinuation.

Conclusion
In conclusion, this meta-analysis suggests that new-onset or worsening of tics
appear to occur at a fairly high rate (5-7%) in the period immediately after starting
psychostimulants. However, tics were no more likely to be associated with
psychostimulant treatment than with placebo. When tics occur in temporal relationship to
psychostimulant use, this relationship is much more often coincidental than causative.
There are several potential confounding factors that may explain the high-rate of tics
reported in children after starting psychostimulants. The high rate of tics observed in
children with ADHD and the waxing-and-waning nature of tic symptoms may explain
some of this phenomenon [151]. Additionally, tics have been demonstrated to worsen
during periods of stress, excitement, and fatigue [151]. The initiation of psychostimulants
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often coincides with the start of the academic year or in the face of increasing
academic/social difficulties – natural periods of high stress, excitement and fatigue for
children. Therefore, the temporal relationship between psychostimulant use and newonset tics could be largely or completely attributable to confounding. Future research
investigating side-effects associated with medications could be greatly enhanced by
requiring pivotal trials to make side-effect data publically available. Additionally, this
research would benefit from a standardized method of reporting and measuring tics and
other side-effects in clinical trials of psychostimulants.
In summary, new-onset or worsening tics are commonly experienced by children
with ADHD in both the active and placebo groups of psychostimulant trials. There is no
evidence of an association between psychostimulant use and risk of new-onset or
worsening tics in placebo-controlled trials. When new-onset or worsening of tics occurs
after the initiation of a psychostimulant medication, it is much more likely to be a result
of coincidence than caused by the medication. Using psychostimulant medications in
children with ADHD and comorbid tics (or with a family history of tics) should be
considered, especially when agents that target both ADHD and tic symptoms (e.g. alpha-2
agonists) have failed. Re-challenging children who experience new-onset or worsening
tics on psychostimulants appears to be a reasonable treatment strategy if ADHD
symptoms remain impairing.
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